Press releases
GSK presents positive results for investigational BRAF and MEK inhibitors dabrafenib and trametinib at ASCO
Findings from GSK’s Phase III clinical study programme evaluating single agent therapy with the targeted anti cancer agents, dabrafenib and trametinib, in patients with BRAF V600 mutation positive metastatic melanoma were presented at the Annual Meeting of the American Society of Clinical Oncology in Chicago.
GSK announces expiration of Hart-Scott-Rodino waiting period for tender offer for HGS
GSK today announced that the waiting period under the HSR Act, as amended, has expired with respect to GSK’s tender offer for all the outstanding shares of Human Genome Sciences.
GSK and EPSRC announce creation of new Chair in Sustainable Chemistry at the University of Nottingham
GSK and The Engineering and Physical Sciences Research Council today announced that they will jointly contribute to the funding for a Chair in Sustainable Chemistry to be based at the planned GSK Carbon Neutral Laboratory for Sustainable Chemistry at the University of Nottingham.
Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade®
GSK announced today that it has submitted regulatory applications in the EU and US related to eltrombopag (Promacta®/Revolade® ) and its use to increase platelet counts in patients with chronic hepatitis C virus infection and low platelets.
GSK secures future of local playing fields with Fields in Trust as part of London 2012 legacy
GSK has today entered a partnership with Fields in Trust (FIT) to secure the future of its Swyncombe Avenue Playing Fields, where hundreds of local people already enjoy sport, by placing them into trust in perpetuity.
GlaxoSmithKline confirms US District Court ruling in Pronova BioPharma’s favour on Lovaza™ patents
GlaxoSmithKline plc (GSK) which has the marketing rights for Lovaza (omega-3-acid ethyl esters) in the US and Puerto Rico, confirmed that U.S. District Judge Sue Lewis Robinson, the presiding judge in the U.S. District Court for the District of Delaware, ruled in Pronova’s favour in Pronova’s patent litigation involving U.S. Patent Nos. 5,656,667 (“’667 patent”) and 5,502,077 (“’077” patent) covering Lovaza.
GSK announces start of Phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 mutation-positive metastatic cutaneous melanoma
GlaxoSmithKline plc. today announced the start of a Phase III programme evaluating the combination of dabrafenib, its BRAF inhibitor, and trametinib, its MEK inhibitor, in patients with BRAF mutation-positive metastatic cutaneous melanoma.
GSK receives positive opinion from European CHMP for pazopanib in the treatment of patients with certain advanced soft tissue sarcomas
GSK announced that the EMA's CHMP has issued a positive opinion recommending marketing authorisation for Votrient for the treatment of adult patients with selective subtypes of advanced STS.
Innovative public-private collaboration launches to tackle antibiotic research
GlaxoSmithKline and AstraZeneca today welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barriers to the development of effective antibiotics.
Two overall winners announced at prestigious national award ceremony in London’s Science Museum
For the first time in its 15 year history the judges of the GlaxoSmithKline (GSK) IMPACT Awards could not choose one overall winner for the awards so instead awarded two prizes. The accolade was received by both the Cornish Women’s Rape and Sexual Abuse Centre (WRSAC) and Target Ovarian Cancer.
